CRISPR corrects DMD in mice for one year in a study supported by Sarepta
[ad_1] In 2017, the manufacturer of drugs for Duchenne Muscular Dystrophy, Sarepta, signed an agreement with Duke University to look for potential treatments for the disease with the help of the editing system. of CRISPR genes. Now, the Duke Lab at the center of this research pact is reporting promising results from a CRISPR trial … Read more